Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

Condition:   Myelodysplastic Syndromes Intervention:   Drug: 50 gm CIVI/24 hours x 5 days every 4 week Sponsors:   New York University School of Medicine;   Perlmutter Cancer Center Not yet recruiting

Source: ClinicalTrials.gov - February 15, 2018 Category: Research Source Type: clinical trials